Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 4—April 2005
Research

Staphylococcus aureus Bacteremia, Australia

Peter Collignon*Comments to Author , Graeme R. Nimmo†, Thomas Gottlieb‡, Iain B. Gosbell§, on behalf of the Australian Group on Antimicrobial Resistance
Author affiliations: *The Canberra Hospital, Garran, Australian Capital Territory, Australia; †Queensland Health Pathology Service, Brisbane, Queensland, Australia; ‡Concord Hospital, Concord, New South Wales, Australia; and; §Southwestern Area Pathology Service, Liverpool, New South Wales, Australia

Main Article

Table 4

International rates and numbers of Staphylococcus aureus bacteremia (SAB)*

Country Y Population SAB/y SAB/105/y % MRSA
Australia
Present report 1998–2002 19,500,000 6,900 35 27
Victoria (25)† 1990–1999 4,502,000 804 27 28
Denmark
Northern Jutland (21) 1996–1998 493,000 155 31 ND
Whole of Denmark (17)‡ 2002 5,350,000 1,488 28 0.6
Ireland (23)§ 1999 3,700,000 ND* 25 36
United Kingdom
England (20,22)¶ 2002–2003
2003 49,200,000 18,403
19,244 37
39 40
41
Northern Ireland (22,24)# 2002
2003 1,697,000 397
569 23
34 38
44
Wales (22)# 2003 2,920,000 742 25 47
USA
Connecticut (14)** 1998 1,124,337 634 56 ND*

*MRSA, methicillin-resistant Staphylococcus aureus; ND, no data given.
†In Victoria, 8,036 SAB episodes were reported, resulting in a rate of 17.8/100,000. The final rate (27.0) for the entire state was extrapolated from this figure. The Victorian scheme is estimated to capture about two thirds of all bacteremia episodes that occur in that state per year.
‡System in place in Denmark since 1960, with numbers of episodes continually rising (e.g., in 1966, 400 per year and total population 4.8 million or 8/100,000). Collection data based on reviewing all discharge summaries and laboratory samples (15 of 16 counties). Associated 23% mortality rate in 2002, and 22% of these deaths were directly related to sepsis.
¶Compulsory reporting system. Unclear if all community onset episodes were included. In England, underreporting occurred with a voluntary system (only 13,770 episodes reported for 2003; thus, a 50% increase with compulsory system) (22).
#This rate is based on voluntary reporting system. Real rate might be 50% higher (22,24).
**Retrospective case analysis. Rate increased with age, urban areas, and African American ethnicity. 15% of community-onset SAB episodes were MRSA.

Main Article

References
  1. Waldvogel  FA. Staphylococcus aureus (including staphylococcal toxic shock). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2000. p. 2069–100.
  2. Cosgrove  SE, Sakoulas  G, Perencevich  EN, Schwaber  MJ, Karchmer  AW, Carmeli  Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–9. DOIPubMedGoogle Scholar
  3. Nimmo  GR, Bell  JM, Mitchell  D, Gosbell  IB, Pearman  JW, Turnidge  JD. Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals 1989–1999. Microb Drug Resist. 2003;9:155–60. DOIPubMedGoogle Scholar
  4. Johnson  LB, Almoujahed  MO, Ilg  K, Maolood  L, Khatib  R. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis. 2003;35:782–9. DOIPubMedGoogle Scholar
  5. Chang  FY, Peacock  JEJ, Musher  DM, Triplett  P, MacDonald  BB, Mylotte  JM, Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003;82:333–9. DOIPubMedGoogle Scholar
  6. Whitby  M, McLaws  ML, Berry  G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust. 2001;175:264–7.PubMedGoogle Scholar
  7. Collignon  P, Gosbell  I, Vickery  A, Nimmo  G, Stylianopoulos  T, Gottlieb  T. Community-acquired methicillin-resistant Staphylococcus aureus in Australia. Lancet. 1998;352:146–7. DOIGoogle Scholar
  8. Cookson  BD. Methicillin-resistant Staphylococcus aureus in the community: new battlefronts, or are the battles lost? Infect Control Hosp Epidemiol. 2000;21:398–403. DOIPubMedGoogle Scholar
  9. Nimmo  GR, Playford  EG. Community-acquired MRSA bacteraemia: four additional cases including one associated with severe pneumonia. Med J Aust. 2003;178:245.PubMedGoogle Scholar
  10. Vandenesch  F, Naimi  T, Enright  MC, Lina  G, Nimmo  GR, Heffernan  H, Community-acquired methicillin resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003;9:978–84.PubMedGoogle Scholar
  11. Faria  N, Oliveira  DC, Westh  H, Monnet  DL, Larsen  AR, Skov  R, A new community-acquired methicillin-resistant Staphylococcus aureus clone circulating in Denmark. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois [Q12: dates?]. Washington: American Society for Microbiology; 2003. p.150.
  12. Coombs  GW, Nimmo  GR, Bell  JM, Huygens  F, O’Brien  FG, Malkowski  MJ, Genetic diversity among community methicillin-resistant Staphylococcus aureus strains causing outpatient infections in Australia. J Clin Microbiol. 2004;42:4735–43. DOIPubMedGoogle Scholar
  13. Australian Hospital Statistics 2001–02. In: Health services series. Canberra: Australian Institute of Health and Welfare; 2003 [cited July 26, 2004]. Available from http://www.aihw.gov.au/publications/hse/ahs01-02/index.html.
  14. Morin  CA, Hadler  JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis. 2001;184:1029–34. DOIPubMedGoogle Scholar
  15. Johnson  AP, Aucken  HM, Cavendish  S, Ganner  M, Wale  MC, Warner  M, Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother. 2001;48:143–4. DOIPubMedGoogle Scholar
  16. Collins  N. Gosbell lB, Wilson SF. Community-acquired MRSA bacteraemia. Med J Aust. 2002;177:55–6.PubMedGoogle Scholar
  17. Danish Staphylococcus aureus bacteremia group. Annual report on Staphylococcus aureus bacteremia in Denmark, 2002. Statens Serum Institut. Published 8/06/2004 [cited July 26, 2004]. Copenhagen. Available from http://www.ssi.dk/graphics/dk/overvagning/Annual02.pdf
  18. Shinefield  H, Black  S, Fattom  A, Horwith  G, Rasgon  S, Ordonez  J, Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491–6. DOIPubMedGoogle Scholar
  19. Valles  J, Rello  J, Ochagavia  A, Garnacho  J, Alcala  MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003;123:1615–24. DOIPubMedGoogle Scholar
  20. The second year of the Department of Health’s mandatory MRSA bacteraemia surveillance scheme in acute Trusts in England: April 2002–March 2003 [cited July 26, 2004] [Available from http://www.hpa.org.uk/cdr/PDFfiles/2003/cdr2503.pdf]. CDR Weekly. 2003;13:1–9.
  21. Schonheyder  HC. Two thousand seven hundred and thirty nine episodes of bacteremia in the county of Northern Jutland 1996–1998. Presentation of a regional clinical database. Ugeskr Laeger. 2000;162:2886–91.PubMedGoogle Scholar
  22. Morgan  M, Salmon  R, Keppie  N, Evans Williams  D, Hosein  I, Looker  DN. All Wales surveillance of methicillin-resistant Staphylococcus aureus (MRSA): the first year’s results. J Hosp Infect. 1999;41:173–9. DOIPubMedGoogle Scholar
  23. McDonald  P, Mitchell  E, Johnson  H, Rossney  A. Epidemiology of MRSA: the North/South study of MRSA in Ireland 1999. J Hosp Infect. 2003;54:130–4. DOIPubMedGoogle Scholar
  24. Staphylococcus aureus bacteraemia: England, Wales and Northern Ireland, January to December 2002 [cited July 26, 2004]. Available from http://www.hpa.org.uk/cdr/PDFfiles/2004/staph_ann_1604.pdf
  25. Veitch  M. Staphylococcus aureus bacteraemia in Victoria, 1990–1999. In: Communicable Diseases Network of Australia Conference. Canberra, Australia: 2001. p. 18, no. 23 [cited July 26,2004]. Available from http://www.cda.gov.au/cdna/pdf/cdc01abs.pdf.
  26. An Expert Working Group of the Australian Infection Control Association. National surveillance of healthcare associated infection in Australia. 2001 [cited July 26, 2004]. Available from http://www.health.gov.au/pubhlth/strateg/jetacar/pdf/scope.pdf.
  27. Okuma  K, Iwakawa  K, Turnidge  JD, Grubb  WB, Bell  JM, O’Brien  FG, Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol. 2002;40:4289–94. DOIPubMedGoogle Scholar
  28. Munckhof  WJ, Schooneveldt  J, Coombs  GW, Hoare  J, Nimmo  GR. Emergence of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infection in Queensland, Australia. Int J Infect Dis. 2003;7:259–67. DOIPubMedGoogle Scholar
  29. Gosbell  IB, Mercer  JL, Neville  SA, Crone  SA, Chant  KG, Jalaludin  BB, Non-multiresistant and multiresistant methicillin-resistant Staphylococcus aureus in community-acquired infections. Med J Aust. 2001;174:627–30.PubMedGoogle Scholar
  30. Nimmo  GR, Schooneveldt  J, O’Kane  G, McCall  B, Vickery  A. Community acquisition of gentamicin-sensitive MRSA in south-east Queensland. J Clin Microbiol. 2000;38:3926–31.PubMedGoogle Scholar

Main Article

1Australian Group on Antimicrobial Resistance contributors to this study were the following: Thomas Gottlieb, Concord Hospital; David McGechie, Denise Daley, Fremantle Hospital; John Ferguson, John Hunter Hospital; James Branley, Nepean Hospital; Graeme R. Nimmo, Princes Alexandria Hospital; Gary Lum, Royal Darwin Hospital; Alistair McGregor, Royal Hobart Hospital; Clarence Fernandes, Royal North Shore Hospital; Iain Gosbell, Archie Darbar, South West Area Health Service, New South Wales; Peter Collignon, Jan Roberts, Canberra Hospital.

Page created: May 26, 2011
Page updated: May 26, 2011
Page reviewed: May 26, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external